Theradex Oncology appointed CRO for Alligator Biosciences’s ATOR-1015 phase I study

Alligator Biosciences affirmed the appointment of Theradex Oncology as CRO for the planned phase I study of ATOR-1015 for the treatment of metastatic cancer anticipated to begin in the second half of 2018. The upcoming clinical phase I study with ATOR-1015 is a first-in-human dose escalation study in patients with metastatic cancer. The study will be conducted at five sites in Sweden and Denmark. Theradex Oncology,  a global contract research organization exhibiting immense expertise in oncology clinical development.

Per Norlén, CEO of Alligator Bioscience said “We have worked previously with Theradex on the ADC-1013 clinical phase I trial and, based on their robust delivery and extensive expertise in clinical oncology research, we are confident in their ability to assist us in executing high-quality studies and we look forward to continuing our successful collaboration.”

ATOR-1015 is a first-in-class bispecific antibody that targets CTLA-4 and OX40 and was created with Alligator’s unique bispecific technology. Alligator has advanced ATOR-1015 through preclinical development and is now preparing for the start of a clinical phase I study.